摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-((4-Chlorophenyl)(piperidin-1-yl)methyl)quinolin-8-ol

中文名称
——
中文别名
——
英文名称
7-((4-Chlorophenyl)(piperidin-1-yl)methyl)quinolin-8-ol
英文别名
7-[(4-chlorophenyl)-piperidin-1-ylmethyl]quinolin-8-ol
7-((4-Chlorophenyl)(piperidin-1-yl)methyl)quinolin-8-ol化学式
CAS
——
化学式
C21H21ClN2O
mdl
——
分子量
352.9
InChiKey
FAICDHONZUTPJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    36.4
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES
    申请人:Eutropics Pharmaceuticals, Inc.
    公开号:US20150133450A1
    公开(公告)日:2015-05-14
    The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    本发明涉及公式I、II和III化合物的组合物和用于癌症治疗的方法。在某些方面,本发明涉及治疗B细胞淋巴瘤或其他造血系统癌症的方法。在其他方面,本发明提供了治疗特定类型造血系统癌症的方法,例如,使用公式I、II和III化合物的一种或多种组合物治疗B细胞淋巴瘤。还包括与26S蛋白酶抑制剂(例如Bortezomib)的组合疗法。在另一个方面,本发明涉及使用公式I、II和III化合物的自身免疫治疗。在另一个方面,本发明涉及识别化合物的方法,例如BH3类似物类化合物,具有预测体外有效性对抗B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的体内功效的特性。
  • Methods and compositions useful for treating diseases involving Bcl-2 family proteins with quinoline derivatives
    申请人:Eutropics Pharmaceuticals, Inc.
    公开号:US10765673B2
    公开(公告)日:2020-09-08
    The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    本发明涉及由式I、II和III化合物组成的治疗癌症的组合物和方法。在某些方面,本发明涉及 B 细胞淋巴瘤或其他造血癌症的治疗。在其它方面,本发明提供了使用一种或多种式I、II和III化合物组合治疗特定类型造血癌症,例如,B细胞淋巴瘤的方法。还包括与例如 26S 蛋白酶抑制剂(如硼替佐米)的联合疗法。在另一方面,本发明涉及用式 I、II 和 III 的化合物进行自身免疫治疗。在另一方面,本发明涉及鉴定化合物的方法,例如,BH3模拟类化合物,其体外特性可预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫性疾病的疗效。
查看更多